• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.

作者信息

Gerstner Elizabeth R, Frosch Matthew P, Batchelor Tracy T

机构信息

Departments of Neurology and Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.

出版信息

J Clin Oncol. 2010 Feb 20;28(6):e91-3. doi: 10.1200/JCO.2009.25.0233. Epub 2009 Nov 23.

DOI:10.1200/JCO.2009.25.0233
PMID:19933906
Abstract
摘要

相似文献

1
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.扩散磁共振成像检测到一名接受贝伐单抗治疗的复发性胶质母细胞瘤患者出现经病理证实的非强化性肿瘤进展。
J Clin Oncol. 2010 Feb 20;28(6):e91-3. doi: 10.1200/JCO.2009.25.0233. Epub 2009 Nov 23.
2
Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.在一名接受贝伐单抗治疗的复发性胶质母细胞瘤患者中，通过动脉自旋标记灌注磁共振成像和磁敏感加权成像对肿瘤对抗血管生成治疗的反应进行早期评估。
J Clin Oncol. 2011 Apr 10;29(11):e308-11. doi: 10.1200/JCO.2010.32.6082. Epub 2011 Jan 24.
3
Bevacizumab plus irinotecan in recurrent glioblastoma.贝伐单抗联合伊立替康治疗复发性胶质母细胞瘤
J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013. doi: 10.1200/JCO.2007.15.1605.
4
Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?贝伐单抗诱导的胶质瘤患者弥散受限：肿瘤进展还是缺氧的替代标志物？
J Clin Oncol. 2010 Sep 20;28(27):e477; author reply e478. doi: 10.1200/JCO.2010.29.2029. Epub 2010 Jun 28.
5
[Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].[评估表观扩散系数（ADC）图作为贝伐单抗/伊立替康治疗复发性胶质瘤化疗疗效早期预测指标的原理验证]
Rofo. 2010 Oct;182(10):868-72. doi: 10.1055/s-0029-1245570. Epub 2010 Aug 25.
6
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.贝伐单抗联合替莫唑胺治疗复发性多形性胶质母细胞瘤患者后完全缓解
Acta Oncol. 2012 Apr;51(4):544-6. doi: 10.3109/0284186X.2011.644251. Epub 2011 Dec 27.
7
Bevacizumab and recurrent malignant gliomas: a European perspective.贝伐单抗与复发性恶性胶质瘤：欧洲视角
J Clin Oncol. 2010 Apr 20;28(12):e188-9; author reply e190-2. doi: 10.1200/JCO.2009.26.9027. Epub 2010 Feb 16.
8
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.贝伐珠单抗治疗后复发性胶质母细胞瘤仅 FLAIR 进展并不预示着生存期短。
Oncology. 2013;85(3):191-5. doi: 10.1159/000354692. Epub 2013 Sep 5.
9
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.复发性胶质母细胞瘤患者使用贝伐珠单抗治疗后的进展模式。
Neurology. 2011 Feb 1;76(5):432-7. doi: 10.1212/WNL.0b013e31820a0a8a.
10
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.贝伐珠单抗治疗后早期增强 MRI 进展作为复发性胶质母细胞瘤总生存期的预后标志物：来自 ACRIN 6677/RTOG 0625 中心读片研究的结果。
Neuro Oncol. 2013 Jul;15(7):945-54. doi: 10.1093/neuonc/not049. Epub 2013 Jun 19.

引用本文的文献

1
RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.RANO 2.0：神经肿瘤学放射学评估的关键更新与实际考量
Jpn J Radiol. 2025 Jun 30. doi: 10.1007/s11604-025-01821-6.
2
The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.利用表观扩散系数值鉴别胶质母细胞瘤中贝伐单抗相关细胞毒性与肿瘤复发及放射性坏死
Cancers (Basel). 2024 Jul 2;16(13):2440. doi: 10.3390/cancers16132440.
3
"Vanishing" glioblastoma: A case report and review of the literature.
“消失型”胶质母细胞瘤：一例病例报告及文献综述
Radiol Case Rep. 2024 May 18;19(8):3276-3282. doi: 10.1016/j.radcr.2024.04.040. eCollection 2024 Aug.
4
The relationship between radiation dose and bevacizumab-related imaging abnormality in patients with brain tumors: A voxel-wise normal tissue complication probability (NTCP) analysis.脑肿瘤患者的辐射剂量与贝伐珠单抗相关的影像学异常之间的关系：体素-wise 正常组织并发症概率（NTCP）分析。
PLoS One. 2023 Feb 17;18(2):e0279812. doi: 10.1371/journal.pone.0279812. eCollection 2023.
5
Intravoxel incoherent motion diffusion-weighted imaging for early assessment of combined anti-angiogenic/chemotherapy for colorectal cancer liver metastases.体素内不相干运动扩散加权成像用于结直肠癌肝转移联合抗血管生成/化疗的早期评估
Quant Imaging Med Surg. 2022 Sep;12(9):4587-4600. doi: 10.21037/qims-21-1220.
6
Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy.靶向胶质母细胞瘤干细胞：关于生物标志物、信号通路和靶向治疗的综述
Front Oncol. 2021 Jul 8;11:701291. doi: 10.3389/fonc.2021.701291. eCollection 2021.
7
Macrophages and microglia: the cerberus of glioblastoma.巨噬细胞和小胶质细胞：胶质母细胞瘤的三头犬。
Acta Neuropathol Commun. 2021 Mar 25;9(1):54. doi: 10.1186/s40478-021-01156-z.
8
Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria.高级别胶质瘤反应的标准化MRI评估：RANO标准的基本要素与陷阱综述
Neurooncol Pract. 2016 Mar;3(1):59-67. doi: 10.1093/nop/npv023. Epub 2015 Jul 12.
9
Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.通过扩散峰度成像对复发性胶质母细胞瘤贝伐单抗治疗反应的早期评估：初步报告。
Neuroradiol J. 2019 Oct;32(5):317-327. doi: 10.1177/1971400919861409. Epub 2019 Jul 8.
10
F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions.F-DOPA PET/CT 在脑肿瘤中的应用：对多学科脑肿瘤委员会决策的影响。
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):558-568. doi: 10.1007/s00259-018-4240-8. Epub 2019 Jan 5.